Frazier Life Sciences Management, L.P.
Frazier Life Sciences Management, L.P. is a healthcare-focused investment firm headquartered in Palo Alto, CA, USA. It manages both venture and public investment funds targeting novel therapeutic companies. Founded in 2005, the firm specializes in company creation, early stage venture investments, and public biotech investments. The firm manages several billion dollars in assets and employs a team of professionals with deep domain expertise in life sciences, serving entrepreneurs, private and public biotech companies, and institutional investors.
Investment Strategy
Frazier Life Sciences pursues investments in therapeutics companies across all stages, with its Venture Funds focusing on the creation and early-stage private companies (over 30 companies created since 2005) and Series A/B opportunities. The Public Funds deploy capital to small- and mid-cap public biotech firms through PIPEs, CMPOs, IPOs, and open market support. The firm's approach emphasizes partnering closely with entrepreneurs and management teams to build valuable companies and advance novel therapeutics for patients. They have raised multi-billion dollar funds and invest globally in therapeutics innovation.
Top Holdings
Equity Positions (48)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
M MIRM | MIRUM PHARMACEUTICALS INC | 13.83% | $345.8M | 6,795,121 | $26.20 | $50.89 | +$39.7M |
V VRNA | VERONA PHARMA PLC | 12.80% | $320.1M | 3,383,950 | $15.98 | $94.58 | +$100.5M |
N NAMS | NEWAMSTERDAM PHARMA COMPANY | 12.03% | $300.8M | 16,607,074 | $14.20 | $18.11 | -$29.1M |
B BBIO | BRIDGEBIO PHARMA INC | 6.56% | $164.1M | 3,800,457 | $21.95 | $43.18 | +$32.7M |
A ARQT | ARCUTIS BIOTHERAPEUTICS INC | 5.54% | $138.4M | 9,874,511 | $18.53 | $14.02 | +$1.0M |